Immunoprevention of cancer poses a challenge to pharmacological research

Pharmacological Research

Volumn 35, Issue 5, 1997, Pages 391-401

  Hrelia, Patrizia ^a   Tanneberger, Stephan ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

Biological response modifiers; Carcinogenesis; Chemoprevention; Immunoregulators; Interferon

Indexed keywords

ADVANCED CANCER; CANCER CONTROL; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; IMMUNOPROPHYLAXIS; IMMUNOREGULATION; IMMUNOTHERAPY; LATENT PERIOD; MEDICAL ETHICS; PRECANCER; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; SOCIAL ASPECT;

EID: 0031149625     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0171     Document Type: Review

References (128)

1. Doll R, Fraumeni JF Jr, Muir CS. Trends in cancer incidence and mortality. 1994;Laboratory Press, Cold Spring Harbor.
2. Tomatis L. Socioeconomic factors and human cancer. Int J Cancer. 62:1995;121-125.
3. Levi F, Te VC, Randimbison L, La Vecchia C. Trends in cancer incidence and mortality in Vaud, Switzerland, 1974-1993. Ann Oncol. 7:1996;497-504.
4. Sporn M. Carcinogenesis and cancer: different perspective on the same disease. Cancer Res. 51:1991;6215-6218.
5. Huber BE, Lazo JS. Gene therapy for neoplastic diseases. Ann New York Acad Sci. 716:1994;4-4.
6. Franks LM. What is cancer? Introduction to the cellular and molecular biology of cancer. 1986;Oxford University Press, Oxford, New York, Tokyo.
7. Tanneberger S, Gummel H, Rieche K, Berndt H. Einige Bemerkungen zum Kreb-Mehrschritt-Therapiekonzept Prof. M. von Ardennes. Dtsches. Gesundheitswesen. 28:1973;1441-1445.
8. Connors T. Is there a future for cancer chemotherapy? Ann Oncol. 7:1996;445-453.
9. Tanneberger S, Timo. fattori timici e cancro. Robustelli della Cuna G. Progressi in Oncologia Clinica. 1992;EDIMES, Pavia.
10. Tanneberger S, Pannuti F. Disillusionments and hopes in the field of biological response modifiers. Anticancer Res. 13:1993;185-192.
11. Tanneberger S. Interferone in der Krebsbehandlung: gestern heute und morgen. Z arztl Fortbild. 88:1994;381-392.
12. Tanneberger S, Hrelia P. Interferons in precancer and cancer prevention: where are we? J Interferon Cytokine Res. 16:1996;339-346.
13. Gutterman JU. Biologic therapy of human cancer. Cancer. Suppl:1992;906-908.
14. Herberman RB. Cell-mediated immunity to tumor cells. Adv Cancer Res. 19:1974;207-263.
15. Penn I. Depressed immunity and the development of cancer. Clin Exp Immunol. 46:1981;459-474.
16. Balkwill FR, Fiers W. Biological response modifiers. Cancer Surveys. 8(4):1989;1-927.
17. Allemand I, Grimber G, Komprobst M, Bennoun M, Molina T, Briand P, Joulin V. Compensatory apoptosis in response to SV 40 large T antigen expression in the liver. Oncogen. 11/12:1995;2583-2590.
18. Sporn MB. Symposium on early lesions and the development of epithelial cancer. Cancer Res. 36:1976;2475-2706.
19. Oortmarsen GJ, Habbema JDF. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Brit J Cancer. 64:1991;559-565.
20. Challis GB, Stam HJ. The spontaneous regression of cancer. Acta Oncologia. 29(5):1990;545-550.
21. Tirelli U, Vaccher E, Zagonel V, Rezza G, Palmieri H, Giovannella Pizzocaro G, Parinello A, Carbonen A, Monfardini S. Malignant tumors other than lymphoma and Kaposi's sarcoma in association with HIV infection. Cancer Detect Prevent. 12:1988;267-272.
22. Penn I. Secundary neoplasms as a consequence of transplantation and cancer therapy. Cancer Detect Prevent. 12:1988;39-57.
23. Bovberg DH, Valdimarsdottir. Familial cancer, emotional distress, and low natural cytotoxic activity in healthy women. Ann Oncol. 4:1993;745-753.
24. Wustrow TPU, Mahnke CG. Cause of immunosuppression in squamous cell carcinoma of the head and neck. Anticancer Res. 16:1996;2433-2468.
25. Kawade Y. Cytokine network in analogy to language. A general view of interferon research from a distance. J Interferon Res. 1991;-Special Issue January - Special Issue January.
26. Shin DM, Kim J, Ro J, Hittelman J, Roth JA, Hong WK, Hittelman WN. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 54:1994;321-326.
27. Yron I, Schickler M, Fisch Pinkas H, Ovadia J, Witz P. The immune system during the pre-cancer and the early cancer period. IL-2 production by PBL from post-menopausal women with and without endometrial carcinoma. Int J Cancer. 38:1986;331-338.
28. Wei WZ, Fulton A, Winkelhake J. Correlation of natural killer activity with tumorigenesis of preneoplastic mouse mammary lesion. Cancer Res. 49:1989;2709-2715.
29. Pillai MR, Balaram P, Kannan S. Interferon activation of latent natural killer cells and alteration in kinetics of target cell lysis: Clinical implications for oral precancerous lesions. Oral Surg Oral Med Oral Pathol. 70 (4):1990;458-461.
30. Anstey AV, Arlett CF, Cole J, Norris PG, Hamblin AS, Limb GA, Lehmann AR, Wilkinso JD, Turner M. Long-term survival and preservation of natural killer cell activity in xeroderma pigmentosum patient with spontaneous regression and multiple deposits of malignant melanoma. Brit J Dermatol. 125:1991;272-278.
31. 01. Proc Natl Acad Sci USA. 77:1980;1471-1474.
32. Taylor-Papadimitriou J. Effects of interferons on cell growth and function. Gessner I. Interferon. 1980;Academic Press Inc. New York.
33. van der Bosch J, Zirvi KA. Growth state-specific responsiveness of primary cultures of a nude mouse-xenografted human colon carcinoma to 4′-deoxydoxorubicin and a crude human leucocyte alpha interferon preparation. Cancer Res. 42:1982;3789-3792.
34. Vorontsova AL, Garina GB, Kudriavets II. The cellular sensitivity of the primary tumor and its metastasis in breast cancer patients to cytostatics, IF and TNF. Vopr Oncol. 35 (11):1989;1315-1318.
35. Urata M, Yoshida H, Yanagawa T. Interferon activity and its characterization in the sera of patients with premalignant lesions arising in oral mucosa. Int J Oral Maxillofac Surg. 15:1986;134-147.
36. Elsasser-Beile U, Kleist S, Fischer R, Monting JS. Impaired cytokine production in whole blood cell cultures from patients with colorectal carcinoma as compared to benign colorectal tumors and controls. J Clin Lab Anal. 6 (5):1992;311-314.
37. Sugerman PB, Savage NW, Xu LJ, Walsh LJ, Seymour GJ. Heat shock protein expression in oral epithelial dysplasia and squamous cell carcinoma. Eur J Cancer. 31B:1995;63-67.
38. Bespalov VG, Troian DN, Petrov AS. Inhibiting effect of thymogen on the development of tumors of the esophagus and forestomach induced by N-nitrosarcosine ethylester in rats. Eksp Oncol. 11 (4):1989;23-26.
39. Tomazic VJ, Sacasa CR, Loftus A. Thymic factor induced reduction of pulmonary metastasis in mice with FSA-fibrosarcoma. Clin Exp Metastasis. 6:1988;17-25.
40. Klein AS, Shoham J. Effect of the thymic factor thymostimulin (TP-1) on the survival rate of tumor-bearing mice. Cancer Res. 41:1981;3217-3221.
41. Fagerberg J, Rubio C, Gresser I, Kuylenstierna R, Munck-Wikland E, Strander H. Interferon-a/b can impede development of carcinogen-induced squamous-cell tumors in the esophagus of C57B1 mice. Int J Cancer. 62:1995;103-106.
42. Herr HW. Immunotherapy of bladder tumors. Uremia Investigation. 8 (3&4):1984/85;257-261.
43. van der Meijden APM, Steerenberg PA, de Jong WH. Intravesical Bacillus Calmette Guerin treatment for superficial bladder cancer: results after 15 years of experience. Anticancer Research. 11:1990;1253-1258.
44. Williams RD. Intravesical interferon-a in the treatment of superficial bladder cancer. Sem Oncol. 15 (5):1988;10-13.
45. Boccardo F, Cannata D, Rubagotti A, Guarneri D, Decensi A, Canobbio L, Curotto A, Martorana G, Pegaoraro C. Prophylaxis of superficial bladder cancer with mitomycin or interferon-alpha-2b. J Clin Oncol. 12 (1):1994;7-13.
46. Lamm DL. BCG in perspective: Advances in the treatment of superficial bladder cancer. Eur Urol. 27 (Suppl. 1):1995;2-8.
47. Stravoravdi, P, Belinasis, J, Dimopoulos, T, 1993, Ultrastructural and clinical study of the urothelium after interferon treatment, Fourth International Congress on Anticancer Chemotherapy, Feb. 2-5, 1993, Paris.
48. Rustin GJS, Kaye SB, Williams CJ. Response of differentiated but not anaplastic teratoma to interferon. Br J Cancer. 50:1984;611-616.
49. Sato M, Yoshida H, Yanagawa T. Therapeutic effect of human fibroblast interferon on premalignant lesions arising in oral mucosa. Int J Oral Surg. 14:1985;184-194.
50. Urata M, Yoshida H, Yanagawa T. Interferon activity and its characterization in the sera of patients with premalignant lesions arising in oral mucosa. Int J Oral Maxillofac Surg. 15:1986;134-147.
51. Pillai MR, Balaram P, Kannan S. Interferon activation of latent natural killer cells and alteration in kinetics of target cell lysis: Clinical implications for oral precancerous lesions. Oral Surg Oral Med Path. 70:1990;458-461.
52. Richtsmeyer W. Biologic modifiers and chemoprevention of cancer of the oral cavity. New Engl J Med. 328:1993;58-59.
53. Osnengo G, Maina G, Gordini G. Beta interferone intralesionala piu timopentina sistemica. Valutazione su 35 CIN III a 2 VAIN III associate ad HPV. Minerva Ginecol. 42:1990;123-128.
54. Zarcone R, Cardone G, Addonizio D. Therapeutic scheme for treatment of HPV infection through use of alpha interferon as intramuscular injection. Our experience in preneoplastic pathology of uterine cervix associated to cytopathic effect of virus. Minerva Ginecol. 44:1992;193-195.
55. D'Aloysio D, Miliffi L, Iannicelli T, Penacchioni O, Bottiglione F. Intramuscular interferon-beta treatment of cervical intraepithelial neoplasia II associated with human papilloma virus infection. Acta Obstet Gyn Scand. 73 (5):1994;420-424.
56. Garzetti GG, Clavattini A, Romanini C, Goteri G, Tarnquilli AL, Muzzioli M. Interferon alpha 2b treatment of cervical intraepithelial neoplasia grade 2: Modulation of natural killer cells. Gyn Obst Investig. 37:1994;204-209.
57. Gasparian MG, Dzhagatspanian NG, Gevorkian RA. The experimental and clinical action of the interferon inducer. Larifan Vopr Virusol. 36:1991;127-130.
58. Gross G, Roussaki A, Papendick U. Efficacy of Interferons on Bowenoid Papulosis and other Precancerous Lesions. J Invest Dermatol. 95 (6):1990;152S-157S.
59. Puligheddu P, Marcello C, Medda F. Activity of Interferon bin Condylomata with dysplastic lesion of the uterine cervix. Eur J Gyn Oncol. IX (2):1988;161-162.
60. White CW, Sondheimer HM, Wilson H. Treatment of pulmonary hemangiomatosis with recombinant interferon-alpha 2a. N Engl J Med. 320:1989;1197-1200.
61. Goepfert H, Sessions RB, Gutterman JU. Leucocyte interferon in patients with juvenile laryngeal papillomatosis. Ann Otol Laryngol. 91:1982;413-436.
62. Oon C. Long-term survival following treatment of hepatocellular carcinoma in Singapore: Evaluation of Welferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol. 31 (Supp.):1992;S137-S142.
63. Uchibayashi T, Koshida K, Nagano K. Effects of prophylactic use of alpha interferon for patients with renal cancer. Int J Oncol. 4/5:1994;1111-1114.
64. Kellof GJ, Boone CW, Malone W, Steele V. Recent results in preclinical and clinical drug development of chemopreventive agents at the National Cancer Institut. Bronzetti H, Hayatsu S, De Flora S, Waters MD, Shankel DM. Antimutagenesis and anticarcinogenesis mechanisms III. 1993;Plenum Press, New York.
65. De Flora S, Ramel C. Mechanisms of inhibitors of mutagenesis and carcinogenesis. Mauta Res. 202:1988;285-306.
66. Tomatis L. Cancer: causes, occurrence and control. IARC Scientific Publications. No. 100:1990.
67. Peplinski GR, Tsung K, Meko JB, Norton JA. Prevention by murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccine viruses. Ann Surg Oncol. 3:1996;15-23.
68. Coughlin CM, Wysocka M, Kurzawa HL, Lee WN, Trinchieri G, Eck SL. B7-1 and interleukin 12 synergistically induce effective antitumor activity. Cancer Res. 55 (21):1995;4980-4987.
69. Fiala ES, Bobotas G, Kulakis C, Wattenberg LW, Weisburger JH. The effects of disulfiram and related compounds on the in vivo metabolism of the colon carcinogen 1,2-dimethylhydrazine. Biochem Pharmacol. 26:1977;1763-1768.
70. Wargovich MJ, Woods C, Eng VWS, Stephens LC, Gray K. Chemoprevention ofN. Cancer Res. 48:1988;6872-6875.
71. Tadi PP, Teel RW, Lau BHS. Organosulfur compounds of garlic modulate mutagenesis, metabolism and DNA binding of aflatoxin B1. Nutr Cancer. 15:1991;87-95.
72. Wattenberg LW. Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothiocianate and related compounds. J Natl Cancer Inst. 58:1977;395-398.
73. Morse MA, Amin SG, Hecht SS, Chung FL. Effect of aromatic isothiocyanates on tumorigenicity, O6-methylguanine formation and metabolism of tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Cancer Res. 49:1989;2894-2897.
74. Reiners JJ Jr, Crowe D, Mckeown C, Nerland DE, Sonnenfeld G. Gamma interferon induction depresses murine hepatic promutagen/procarcinogen activation. Carcinogenesis. 5:1984;125-128.
75. Reiners JJ Jr. Interferon-beta inhibits 7,12-dimethylbenzo[a]anthracene-dependent mutagenesis in a keratinocyte cell-mediated mutation assay. Carcinogenesis. 6:1985;1781-1785.
76. Hrelia P, Morotti M, Vigagni F, Maffei F, Paolini M, Mesirca R, Cantelli Forti G. The modulating activity of interferon on benzo[a]pyrene bioactivation and clastogenesis in mice. Pharmacol Toxicol. 74:1994;249-254.
77. Mannerring GJ, Deloria LB. The pharmacology and toxicology of the interferons: an overview. Annu Rev Pharmacol Toxicol. 26:1996;455-515.
78. Tamm I, Jasny BR, Pfeffer WJ, Tamm L. Antiproliferative action of interferons. Pfeffer LM. Mechanisms of interferon action. 1987;CRC Press, Boca Raton.
79. Vant'hull S, Schellekens H, Lowenberg B, De Vries MJ. Influence of interferon preparation on the proliferative capacity of human and mouse bone marrow cellsin vitro. Cancer Res. 38:1978;911-914.
80. Sreevalsan T, Rosengurt E, Taylor-Papadimitriov J, Burchell J. Differential effect of interferon on DNA synthesis, 2-deoxyglucose uptake and ornithine decarboxylase activity in 3T3 cells stimulated by polypeptide growth factors and tumor promoters. J Cell Physiol. 104:1980;1-19.
81. Atallah AM, Fleischer T, Neefe JR, Kazakis A. Differential effects of human interferon on normal and neoplastic T- and B-cells lymphocytes. Ann NY Acad Sci. 350:1980;245-247.
82. Kishada T, Toda S, Toida A, Hattori T. Effect de l'interferon sur le cellule maligne de la souris. CR Soc Biol. 165:1971;1489-1492.
83. Salerno RA, Whitmire CE, Garcia IM, Heubner RJ. Chemical carcinogenesis in mice inhibited by interferon. Nature. 239:1972;31-32.
84. Pandya KP, Shanker R, Guota A, Khan WA, Ray PK. Modulation of benzene toxicity by an interferon inducer (6MFA). Toxicology. 39:1986;291-305.
85. Lippman SM, Glisson BS, Karanagh JJ, Loton R, Hong WK, Paredes-Espinoza M, Hittelman WN, Holdener EE, Krakoff IH. Retinoic acid and interferon combination studies in human cancer. Eur J Cancer. 29A Suppl. 5:1993;S9-13.
86. Balkwill FR, Mowshowitz S, Seilman SS, Moodie EM, Griffin DB, Fantes KH, Wolf CR. Positive interactions between interferon and chemotherapy due to direct tumor action than effects on host drug-metabolizing enzymes. Cancer Res. 44:1984;5249-5255.
87. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 50:1990;3473-3486.
88. Zasukhina GD, Sinelchikowa TA, Vasilyeva IR, Kirkova ZS. An approach to modification of the repair activity in eukaryotic cells by biological factors. Mutat Res. 81:1981;123-132.
89. Suzuki N, Suzuki H, Kojima T, Sugita K, Takakubo Y, Okamoto S. Effects of human interferon on cellular response to UV in UV-sensitive human cell stains. Mutat Res. 198:1988;207-214.
90. Suzuki N. Effects of human interferon-α Mutat Res. 175:1986;189-193.
91. Wang P, Cong S, Dong X, Chen Z, Ma C. A genetic study of human interferon-α Mutat Res. 262:1991;125-128.
92. Pastorino U. Nutrition and chemoprevention controversies. Ann Oncol. 4:1993;117-120.
93. Boyle P, Chiesa F, Scully C. Chemoprevention and oral cancer - (more) trial and (more) tribulations. Eur J Cancer. 31A:1995;1-12.
94. Scully C. Oral precancer: preventive and medical approaches to management. Eur J Cancer. 31B:1995;16-26.
95. Lotan R. Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Anticancer Res. 16:1996;2415-2420.
96. Lippman SM, Heyman RA, Kurie JM, Benner SE, Waun Ki Hong. Retinoids and Chemoprevention: Clinical and basic studies. J Cell Biochem. 58 (Suppl. 22):1995;1-10.
97. Hong WK, Lippman SM, Wolf GT. Recent advances in head and neck cancer - larynx preservation and cancer chemoprevention: the seventeenth annual Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 53:1993;5113-5120.
98. Papadimitrakopoulou VA, Lippman SM, Lee SE, Toth BB, Martin JW, Lee JJ, Batsakis JG, Hittelman WN, Lotan R, Hon WK. Long term follow-up of low-dose isotretinoin (13-cRA) versus beta carotene to prevent oral carcinogenesis. Proc Am Soc Clin Oncol. 15:1996.
99. Aapro MS. Retinoids in Oncology. Eur J Cancer. 31A:1995;834-835.
100. Hirose M, Futakuchi M, Ito N. Chemoprevention of heterocyclic amine induced carcinogenesis by antioxydants. Int Cancer Congress. Symposia:1994.
101. Hecht SS, Staretz ME, Trushin N, Carmella SG, Richi JP, Chung FL, Andersen LM, Rice JM. Chemoprevention in lung cancer with isothiocyanates. Int Cancer Congress. Symposia:1994.
102. De Flora S, D'Agostini FD, Bennicelli C, Camoirano C, Cesarone CF, Albini A, Balansky R. Chemoprevention studies withN. Int Cancer Congress. Symposia:1994;352-352.
103. Jordan VC. What if tamoxifen (ICI 46,474) had been found to produce rat liver tumours in 1973? A personal perspective. Ann Oncol. 6:1995;29-35.
104. Editorial. Tamoxifen in the carcinogen court: Much ado about nothing? Ann Oncol. 7:1996;327-328.
105. Reddy BS, Chintsalapally, Rao V, Jagveer Sing. Chemoprevention in colon cancer. Int Cancer Congress. Symposia:1994.
106. Yamakido M, Ishioka S, Yanagida J, Hozawa S, Matsuzaka S, Yukutake M, Nishimoto Y. The prevention of cancers in man with a biological response modifier. J Cancer Res Clin Oncol. 116:1990;84-84.
107. Taik-Koo Y, Soo Yong C. A case-control study of ginseng intake and cancer. Int J Epidemiol. 19:1990;871-876.
108. Taik-Koo Y, Soo-Yong C, Yun-Sil L. A cohort study on ginseng intake and cancer for population over 40-years old in ginseng production area, Kangwha-eup. Int Cancer Congress. 1994;PSPR2-PSP33.
109. Toma S, Palumbo R, Rosso R. Results, toxicity and compliance in chemoprevention trials of head and neck cancer. Eur J Cancer Prev. 3:1994;63-68.
110. Costa A, Formelli F, Chiesa F, Decensi F, De Palo G, Veronesi U. Prospects of chemoprevention of human cancers with synthetic retinoid fenretinide. Cancer Res. 54 (Suppl.):1994;2032s-2037s.
111. Gresser I, Tovey MG, Maury C, Chouroulinkoy B. Lethality of interferon preparations for newborn mice. Nature. 258:1975;76-78.
112. Thestrup-Pedersen K, Esman V, Jensen IR, Hastrup J, Thorling K, Saemundsen AK, Bisballe S, Pallesen G, Madsen M, Masucce G, Ernberg I. Epstein-Barr-Virus induced lymphoproliferative disorder converting to fatal Burkitt-like lymphoma in a boy with interferon-inducible chromosomal defect. Lancet. 2:1980;997-1002.
113. Benedict WF, Baker MS, Haroun L, Choi E, Ames BN. Mutagenicity of cancer chemotherapeutic agents in the Salmonella microsome test. Cancer Res. 37:1977;2209-2213.
114. Shimada H, Ebine Y, Kurosawa Y, Arauchi T. Mutagenicity studies of human fibroblast interferon (Hu IFN-b). Mutat Res. 139:1984;183-187.
115. Jones G, Itri LM. Safety and tolerance of recombinant alpha-2a interferon in cancer patients. Cancer. 57:1986;1709-1715.
116. Williams SJ, Farrel GC. Inhibition of antipyrin metabolism by interferon. Br J Clin Pharmacol. 22:1986;610-612.
117. Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet. 2:1987;939-941.
118. Okuna H, Kitada Y, Takasu M, Kano H, Kumeida K, Seki T, Shiozaki Y, Sameshina Y. Depression of drug metabolizing activity in human liver by interferon-a. Eur J Clin Pharmakol. 39:1990;365-367.
119. Donato MT, Herreo E, Gomez-Lechon MJ, Castell JV. Inhibition of monooxygenase activities in human hepatocytes by interferons. Toxicol in vitro. 7:1993;481-485.
120. Yarosh DB, Kripke MA. DNA repair and cytokine in antimutagenesis and anticarcinogenesis. Mutat Res. 350:1996;255-260.
121. Maltoni C, Soffritti M, Davis W. The scientific bases of cancer chemoprevention. 1996;Elsevier, Amsterdam, Lousanne, New York, Oxford, Shannon, Tokyo.
122. Tanneberger S. When must a new approach to treatment be introduced. Int J Technol Health Care. 4:1988;113-120.
123. WHO. Oral contraceptives and neoplasia. Tech Report. 817:1992.
124. Perera FP. The role of biomarkers in cancer prevention. Int Cancer Congress. Symposia:1994;355-355.
125. Sankaranarayanan R. The need for validation of biomarkers in chemoprevention trials. Int Cancer Congress. Symposia:1994;356-356.
126. Pizzicchetta MA, Giuliotto N, Zottar M, Crivellari D, Foladore S, Veronesi A. Tamoxifen (TAM) as adjuvant after surgery for breast cancer (BC) and Tamoxifen or placebo (TAM/PLAC) as chemoprevention (CP) in healthy women. Different compliance to treatment. Proc Am Soc Clin Oncol. 15:1996;173-173.
127. Bonelli L, Conio M, Picasso M, Massa P, Dodero M, Ravelli P, Missale G, Bruzzi P, Aste H. Chemoprevention of metachronous adenoma of the large bowel: a double blind randomized trial of antioxidants. Int Cancer Congress. PSPR:1994;3-05.
128. Love RR. Tamoxifen chemoprevention: Public health goals, toxicities for all and benefits to a few. Ann Oncol. 6:1995;127-128.